Loading
Adrenal Hormones and Disorders · Journal article
Private Practice Infectious Disease · August 27, 2026
A consensus or society position rather than new primary data.
This is a narrative review that synthesizes existing evidence on glucocorticoid use as adjunctive therapy in infectious diseases, with emphasis on conditions where host inflammation drives morbidity and mortality. The review identifies specific infections (bacterial meningitis, TB meningitis and pericarditis, PCP, COVID-19, septic shock, croup, selected fungal and parasitic infections) for which GC co-administration with antimicrobials is evidence-supported, and explicitly highlights contraindications such as cerebral malaria. The source provides clinical guidance rather than new trial data.
Journal article. Patients with select bacterial, viral, fungal, and parasitic infections in which host inflammation is a major driver of harm..
Glucocorticoids are effective as adjunctive therapy in select infections where host inflammatory response, not direct pathogen toxicity, is the primary driver of morbidity and mortality. Conditions with evidence-based GC indications include bacterial meningitis, TB meningitis and pericarditis, PCP, COVID-19, septic shock, croup, and selected fungal and parasitic infections. Cerebral malaria is explicitly highlighted as a contraindication to glucocorticoid use.
Glucocorticoids are effective as adjunctive therapy in select infections where host inflammatory response, not direct pathogen toxicity, is the primary driver of morbidity and mortality.
Clinicians managing infectious diseases should recognize glucocorticoids as an evidence-supported adjunctive strategy in specific high-inflammation conditions (meningitis, septic shock, severe COVID-19), but only when paired with definitive antimicrobial therapy and after ruling out contraindications such as cerebral malaria. The guidance emphasizes that agent, dose, and duration must be individualized by condition.
A narrative review synthesizing evidence-based clinical indications for glucocorticoid adjunctive use across multiple infectious disease categories, grounded in RCTs and guidelines but not presenting new primary data.
Clinicians managing infectious diseases should recognize glucocorticoids as an evidence-supported adjunctive strategy in specific high-inflammation conditions (meningitis, septic shock, severe COVID-19), but only when paired with definitive antimicrobial therapy and after ruling out contraindications such as cerebral malaria. The guidance emphasizes that agent, dose, and duration must be individualized by condition.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract: Glucocorticoids (GCs) represent a critical adjunctive strategy in the management of select infectious diseases, particularly those in which the host inflammatory response, rather than direct pathogen toxicity, is the primary driver of morbidity and mortality. This review synthesizes evidence-based indications for GC use across bacterial, viral, fungal, and parasitic infections, with emphasis on agent selection, dosing, duration, and the clinical principle that steroids must always be co-administered with definitive antimicrobial therapy. The conditions discussed include bacterial meningitis, tuberculosis (meningitis and pericarditis), PCP, COVID-19, septic shock, croup, and selected fungal and parasitic infections. Contraindications, most notably cerebral malaria, are highlighted. The evidence base ranges from landmark randomized controlled trials to consensus guidelines.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.